The CLTI Paradigm Shift: Implications for Clinical Trial Design and Endpoints in Endovascular Management of Infrapopliteal Disease
Journal of Endovascular Therapy · 2026
DOI: 10.1177/15266028251363541 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endovascular Therapy, 2026. Verfasst von Jihad A Mustapha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lake City Cardiovascular Institute, Lake City, FL, USA. Hauptthemen laut MEDLINE: Endovascular Procedures, Peripheral Arterial Disease, Popliteal Artery, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
The evolution from critical limb ischemia to chronic limb-threatening ischemia (CLTI) necessitates a reevaluation of clinical trial endpoints. Traditional measures like hemodynamic indices and lesion patency inadequately reflect CLTI complexity or patient-centered outcomes. This article explores the limitations of conventional endpoints and proposes a modified definition of clinically-driven target lesion (TL) revascularization (CD-TLR) that addresses inflow, TL, and outflow disease. By incorporating a more comprehensive assessment of vascular health and prioritizing patient-relevant outcomes, this modified CD-TLR definition may better reflect modern CLTI management strategies and improve clinical relevance of trial results in this challenging patient population. Clinical Impact The evolution from CLI to CLTI requires reassessing how we measure treatment success in clinical trials. This review identifies why traditional endpoints like hemodynamic indices, lesion patency, and CD-TLR may not adequately inform clinical decision-making. The importance of measuring outcomes that directly impact patient quality of life will help clinicians better evaluate and apply clinical trial results. An emphasis on limb salvage, wound healing, and functional outcomes, rather than surrogate endpoints alone, will lead to more informed treatment decisions and improved CLTI management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lake City Cardiovascular Institute, Lake City, FL, USA.
- Micro Medical Solutions, Woburn, MA, USA.
- Miller Scientific, Johnson City, TN, USA.
- Miami Cardiac and Vascular Institute, Miami, FL, USA.
- Novant Health Heart and Vascular Institute, Charlotte, NC, USA.
- Vascular Institute of the Midwest, Davenport, IA, USA.
ORCID-Profile: Larry E Miller, Robert E Beasley
Zitieren
APA
Mustapha, J. A., Jacob, R., Miller, L. E., Pena, C. S., AlMahameed, A., Dippel, E. J., Beasley, R. E., & Wiechmann, B. N. (2026). The CLTI Paradigm Shift: Implications for Clinical Trial Design and Endpoints in Endovascular Management of Infrapopliteal Disease. Journal of Endovascular Therapy. https://doi.org/10.1177/15266028251363541
Vancouver
Mustapha JA, Jacob R, Miller LE, Pena CS, AlMahameed A, Dippel EJ, et al. The CLTI Paradigm Shift: Implications for Clinical Trial Design and Endpoints in Endovascular Management of Infrapopliteal Disease. Journal of Endovascular Therapy. 2026. doi:10.1177/15266028251363541
BibTeX
@article{Mustapha2026,
author = {Mustapha, Jihad A and Jacob, Rita and Miller, Larry E and Pena, Constantino S and AlMahameed, Amjad and Dippel, Eric J and Beasley, Robert E and Wiechmann, Bret N},
title = {The CLTI Paradigm Shift: Implications for Clinical Trial Design and Endpoints in Endovascular Management of Infrapopliteal Disease},
journal = {Journal of Endovascular Therapy},
year = {2026},
doi = {10.1177/15266028251363541}
}
EUVIMED